Please enable JavaScript to continue using this application.

Compare $LRMR vs $PALI | Chartloom

Compare

$LRMR vs $PALI

Larimar Therapeutics Inc · Palisade Bio Inc

LRMR

Larimar Therapeutics Inc

PALI

Palisade Bio Inc

Compare $LRMR vs $PALI

Comparing Larimar Therapeutics Inc and Palisade Bio Inc

LRMRLarimar Therapeutics Inc

PALIPalisade Bio Inc

LRMRLarimar Therapeutics Inc

Market cap

$277M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-23.1%

52W performance

-44.6%

FCF yield

-56.3%

PALIPalisade Bio Inc

Market cap

$267M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-38.4%

52W performance

-23.0%

FCF yield

-6.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LRMR

PALI

Detailed metrics comparison

LRMR

Larimar Therapeutics Inc

PALI

Palisade Bio Inc

Market Cap

LRMR$277M

PALI$267M

Enterprise Value

LRMR$185M

PALI$142M

Price

LRMR$2.67

PALI$1.54

P/E Ratio

LRMRN/A

PALIN/A

P/S Ratio

LRMR0.00x

PALI534.63x

EV/Sales

LRMR0.00x

PALI284.28x

EV/EBITDA

LRMR0.00x

PALI0.00x

P/B Ratio

LRMR2.41x

PALI2.06x

P/FCF Ratio

LRMRN/A

PALIN/A

EV/FCF

LRMR-1.18x

PALI-7.81x

PEG Ratio

LRMRN/A

PALIN/A

Forward P/E (NTM)

LRMRN/A

PALIN/A

Forward P/S (NTM)

LRMRN/A

PALIN/A

Revenue (TTM)

LRMR$0

PALI$500K

Revenue Growth (YoY)

LRMRN/A

PALIN/A

Forward Rev Growth

LRMR290.4%

PALI42864.7%

Gross Margin (TTM)

LRMR0.0%

PALI0.0%

Operating Margin (TTM)

LRMR0.0%

PALI0.0%

EBITDA Margin (TTM)

LRMR0.0%

PALI-7069.6%

Net Margin (TTM)

LRMR0.0%

PALI-6388.2%

FCF Margin (TTM)

LRMRN/A

PALI-3638.0%

Net Income (TTM)

LRMR$-173M

PALI$-32M

FCF (TTM)

LRMR$-156M

PALI$-18M

EPS (TTM)

LRMR-$1.66

PALI-$0.15

ROE (TTM)

LRMR-13739.0%

PALI-3347.0%

ROA (TTM)

LRMR-9765.0%

PALI-3179.0%

ROIC (TTM)

LRMR-13739.0%

PALI-3345.0%

Cash

LRMR$93M

PALI$125M

Debt

LRMR$0

PALI$0

Net Cash/Debt

LRMR$93M

PALI$125M

Current Ratio (TTM)

LRMR4.70x

PALI24.26x

Quick Ratio (TTM)

LRMR4.58x

PALI23.97x

Debt/Equity (TTM)

LRMR0.00x

PALI0.00x

Debt/Assets (TTM)

LRMR0.0%

PALI0.0%

Interest Coverage (TTM)

LRMRN/A

PALIN/A

Net Debt/EBITDA (TTM)

LRMR0.00x

PALI0.00x

Beta

LRMR0.68

PALI1.53

52W Performance

LRMR-44.6%

PALI-23.0%

YTD Performance

LRMR-23.1%

PALI-38.4%

% from 52W High

LRMR-58.4%

PALI-46.0%

% from 52W Low

LRMR2.3%

PALI16.7%

Asset Turnover (TTM)

LRMR0.00x

PALI0.00x

FCF Yield (TTM)

LRMR-56.3%

PALI-6.8%

Earnings Yield (TTM)

LRMR-62.2%

PALI-11.9%

Dividend Yield (TTM)

LRMRN/A

PALIN/A

Rule of 40

LRMR0.0

PALI-3,638.0

EV/GP/RG

LRMRN/A

PALIN/A

Ticker research

View LRMR research View PALI research

Metric	LRMR Larimar Therapeutics Inc	PALI Palisade Bio Inc
Market & Valuation
Market Cap	$277M	$267M
Enterprise Value	$185M	$142M
Price	$2.67	$1.54
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	534.63x
EV/Sales	0.00x	284.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.41x	2.06x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.18x	-7.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$500K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	290.4%	42864.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-7069.6%
Net Margin (TTM)	0.0%	-6388.2%
FCF Margin (TTM)	N/A	-3638.0%
Net Income (TTM)	$-173M	$-32M
FCF (TTM)	$-156M	$-18M
EPS (TTM)	-$1.66	-$0.15
ROE (TTM)	-13739.0%	-3347.0%
ROA (TTM)	-9765.0%	-3179.0%
ROIC (TTM)	-13739.0%	-3345.0%
Financial Health
Cash	$93M	$125M
Debt	$0	$0
Net Cash/Debt	$93M	$125M
Current Ratio (TTM)	4.70x	24.26x
Quick Ratio (TTM)	4.58x	23.97x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.68	1.53
52W Performance	-44.6%	-23.0%
YTD Performance	-23.1%	-38.4%
% from 52W High	-58.4%	-46.0%
% from 52W Low	2.3%	16.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-56.3%	-6.8%
Earnings Yield (TTM)	-62.2%	-11.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-3,638.0
EV/GP/RG	N/A	N/A
Ticker research	View LRMR research	View PALI research

Valuation

P/S Ratio

LRMR

0.00x

PALI

534.63x

EV/FCF

PALI

-7.81x

LRMR

-1.18x

Growth & revenue

Forward Revenue Growth

PALI

42864.7%

LRMR

290.4%

Profitability & performance

Gross Margin

LRMR

0.0%

PALI

0.0%

ROE

PALI

-3347.0%

LRMR

-13739.0%

FCF Yield %

PALI

-6.8%

LRMR

-56.3%

52-Week Performance

PALI

-23.0%

LRMR

-44.6%

Detailed metrics comparison

LRMR

Larimar Therapeutics Inc

PALI

Palisade Bio Inc

Market Cap

LRMR$277M

PALI$267M

Enterprise Value

LRMR$185M

PALI$142M

Price

LRMR$2.67

PALI$1.54

P/E Ratio

LRMRN/A

PALIN/A

P/S Ratio

LRMR0.00x

PALI534.63x

EV/Sales

LRMR0.00x

PALI284.28x

EV/EBITDA

LRMR0.00x

PALI0.00x

P/B Ratio

LRMR2.41x

PALI2.06x

P/FCF Ratio

LRMRN/A

PALIN/A

EV/FCF

LRMR-1.18x

PALI-7.81x

PEG Ratio

LRMRN/A

PALIN/A

Forward P/E (NTM)

LRMRN/A

PALIN/A

Forward P/S (NTM)

LRMRN/A

PALIN/A

Revenue (TTM)

LRMR$0

PALI$500K

Revenue Growth (YoY)

LRMRN/A

PALIN/A

Forward Rev Growth

LRMR290.4%

PALI42864.7%

Gross Margin (TTM)

LRMR0.0%

PALI0.0%

Operating Margin (TTM)

LRMR0.0%

PALI0.0%

EBITDA Margin (TTM)

LRMR0.0%

PALI-7069.6%

Net Margin (TTM)

LRMR0.0%

PALI-6388.2%

FCF Margin (TTM)

LRMRN/A

PALI-3638.0%

Net Income (TTM)

LRMR$-173M

PALI$-32M

FCF (TTM)

LRMR$-156M

PALI$-18M

EPS (TTM)

LRMR-$1.66

PALI-$0.15

ROE (TTM)

LRMR-13739.0%

PALI-3347.0%

ROA (TTM)

LRMR-9765.0%

PALI-3179.0%

ROIC (TTM)

LRMR-13739.0%

PALI-3345.0%

Cash

LRMR$93M

PALI$125M

Debt

LRMR$0

PALI$0

Net Cash/Debt

LRMR$93M

PALI$125M

Current Ratio (TTM)

LRMR4.70x

PALI24.26x

Quick Ratio (TTM)

LRMR4.58x

PALI23.97x

Debt/Equity (TTM)

LRMR0.00x

PALI0.00x

Debt/Assets (TTM)

LRMR0.0%

PALI0.0%

Interest Coverage (TTM)

LRMRN/A

PALIN/A

Net Debt/EBITDA (TTM)

LRMR0.00x

PALI0.00x

Beta

LRMR0.68

PALI1.53

52W Performance

LRMR-44.6%

PALI-23.0%

YTD Performance

LRMR-23.1%

PALI-38.4%

% from 52W High

LRMR-58.4%

PALI-46.0%

% from 52W Low

LRMR2.3%

PALI16.7%

Asset Turnover (TTM)

LRMR0.00x

PALI0.00x

FCF Yield (TTM)

LRMR-56.3%

PALI-6.8%

Earnings Yield (TTM)

LRMR-62.2%

PALI-11.9%

Dividend Yield (TTM)

LRMRN/A

PALIN/A

Rule of 40

LRMR0.0

PALI-3,638.0

EV/GP/RG

LRMRN/A

PALIN/A

Ticker research

View LRMR research View PALI research

Metric	LRMR Larimar Therapeutics Inc	PALI Palisade Bio Inc
Market & Valuation
Market Cap	$277M	$267M
Enterprise Value	$185M	$142M
Price	$2.67	$1.54
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	534.63x
EV/Sales	0.00x	284.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.41x	2.06x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.18x	-7.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$500K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	290.4%	42864.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-7069.6%
Net Margin (TTM)	0.0%	-6388.2%
FCF Margin (TTM)	N/A	-3638.0%
Net Income (TTM)	$-173M	$-32M
FCF (TTM)	$-156M	$-18M
EPS (TTM)	-$1.66	-$0.15
ROE (TTM)	-13739.0%	-3347.0%
ROA (TTM)	-9765.0%	-3179.0%
ROIC (TTM)	-13739.0%	-3345.0%
Financial Health
Cash	$93M	$125M
Debt	$0	$0
Net Cash/Debt	$93M	$125M
Current Ratio (TTM)	4.70x	24.26x
Quick Ratio (TTM)	4.58x	23.97x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.68	1.53
52W Performance	-44.6%	-23.0%
YTD Performance	-23.1%	-38.4%
% from 52W High	-58.4%	-46.0%
% from 52W Low	2.3%	16.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-56.3%	-6.8%
Earnings Yield (TTM)	-62.2%	-11.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-3,638.0
EV/GP/RG	N/A	N/A
Ticker research	View LRMR research	View PALI research